Cyxone AB
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, … Read more
Cyxone AB (CYXO) - Total Liabilities
Latest total liabilities as of June 2024: Skr3.46 Million SEK
Based on the latest financial reports, Cyxone AB (CYXO) has total liabilities worth Skr3.46 Million SEK as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cyxone AB - Total Liabilities Trend (2015–2023)
This chart illustrates how Cyxone AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cyxone AB Competitors by Total Liabilities
The table below lists competitors of Cyxone AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Dongsheng International Inc
PINK:CDSG
|
USA | $1.07 Million |
|
NISSAN CHEMICAL IND - Dusseldorf Stock Exchang
DU:NSC
|
Germany | €92.56 Billion |
|
CENTURY ALUMINUM
BE:EY3
|
Germany | €1.27 Billion |
|
Morgan Sindall Group PLC
LSE:MGNS
|
UK | GBX1.57 Billion |
|
Genpact Ltd
STU:35G
|
Germany | €2.84 Billion |
|
TOKIO MARINE
BE:MH6
|
Germany | €25.86 Trillion |
Liability Composition Analysis (2015–2023)
This chart breaks down Cyxone AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cyxone AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cyxone AB (2015–2023)
The table below shows the annual total liabilities of Cyxone AB from 2015 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | Skr4.69 Million | -15.89% |
| 2022-12-31 | Skr5.58 Million | -19.07% |
| 2021-12-31 | Skr6.90 Million | +36.64% |
| 2020-12-31 | Skr5.05 Million | +49.41% |
| 2019-12-31 | Skr3.38 Million | -34.04% |
| 2018-12-31 | Skr5.12 Million | +30.21% |
| 2017-12-31 | Skr3.93 Million | +438.52% |
| 2016-12-31 | Skr730.29K | +128.22% |
| 2015-12-31 | Skr320.00K | -- |